Low-frequency CDKN1B variants in pituitary testing: a diagnostic pitfall

Low variant allele frequency (VAF) variants identified during germline testing may represent constitutional mosaicism or acquired somatic events restricted to hematopoietic cells. Although clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an important source of interpretative pitfalls in hereditary cancer testing, its potential impact on the interpretation of CDKN1B variants has not been specifically emphasized. We aimed to determine whether low-VAF CDKN1B variants detected during routine germline testing for pituitary adenoma predisposition may represent clonal hematopoiesis rather than true constitutional alterations. We analyzed patients referred for routine genetic investigation of pituitary adenoma predisposition in whom low-frequency CDKN1B variants were identified in blood-derived DNA. Additional analyses were performed, including assessment of variant distribution in non-hematopoietic tissues, tumor DNA analysis, and investigation of CHIP-associated genes. Three unrelated patients carrying truncating CDKN1B variants were identified, with blood-derived VAFs ranging from 4% to 6%. Clinical presentations included two gonadotroph macroadenomas diagnosed later than age 70 years and one prolactin-secreting macroadenoma diagnosed before age 35. CDKN1B variants were absent in buccal swab DNA and from available pituitary tumor DNA. Additional pathogenic variants affecting CHIP-associated genes were identified in two individuals. Collectively, these findings supported a leukocyte-restricted origin of the CDKN1B variants and suggested CHIP as the most likely explanation. Low-frequency CDKN1B variants detected during blood-based germline testing should not automatically be interpreted as constitutional mosaicism or inherited endocrine tumor predisposition. Integration of tissue-specific analyses and consideration of CHIP-related findings are essential to avoid inappropriate genetic counseling, unnecessary familial investigations, and misleading surveillance recommendations.

Authors

Institutions

Publication Details

Journal
European Journal of Endocrinology
Published
2026-08-27
DOI
https://doi.org/10.1093/ejendo/lvag165
Primary Topic
Pituitary Gland Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Low-frequency CDKN1B variants in pituitary testing: a diagnostic pitfall

Nadim Hamzaoui, Jérôme Bertherat, Olivier Kosmider, Chloé Friedrich et al.
European Journal of Endocrinology
Pituitary Gland Disorders and Treatments
article

Low-frequency CDKN1B variants in pituitary testing: a diagnostic pitfall

Nadim Hamzaoui, Jérôme Bertherat, Olivier Kosmider, Chloé Friedrich, Éric Pasmant, Emmanuelle Kuhn, Albain Chansavang, Aurélie Toussaint, Alimha Godin
article en

Abstract

Low variant allele frequency (VAF) variants identified during germline testing may represent constitutional mosaicism or acquired somatic events restricted to hematopoietic cells. Although clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an important source of interpretative pitfalls in hereditary cancer testing, its potential impact on the interpretation of CDKN1B variants has not been specifically emphasized. We aimed to determine whether low-VAF CDKN1B variants detected during routine germline testing for pituitary adenoma predisposition may represent clonal hematopoiesis rather than true constitutional alterations. We analyzed patients referred for routine genetic investigation of pituitary adenoma predisposition in whom low-frequency CDKN1B variants were identified in blood-derived DNA. Additional analyses were performed, including assessment of variant distribution in non-hematopoietic tissues, tumor DNA analysis, and investigation of CHIP-associated genes. Three unrelated patients carrying truncating CDKN1B variants were identified, with blood-derived VAFs ranging from 4% to 6%. Clinical presentations included two gonadotroph macroadenomas diagnosed later than age 70 years and one prolactin-secreting macroadenoma diagnosed before age 35. CDKN1B variants were absent in buccal swab DNA and from available pituitary tumor DNA. Additional pathogenic variants affecting CHIP-associated genes were identified in two individuals. Collectively, these findings supported a leukocyte-restricted origin of the CDKN1B variants and suggested CHIP as the most likely explanation. Low-frequency CDKN1B variants detected during blood-based germline testing should not automatically be interpreted as constitutional mosaicism or inherited endocrine tumor predisposition. Integration of tissue-specific analyses and consideration of CHIP-related findings are essential to avoid inappropriate genetic counseling, unnecessary familial investigations, and misleading surveillance recommendations.

European Journal of Endocrinology
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris Cité (FR), Sorbonne Université (FR), Hôpital Cochin (FR), Pitié-Salpêtrière Hospital (FR), Institut Cochin (FR), Institut Curie (FR)
Peace, Justice and strong institutions
Openalex Percentile: Top 10%
Pituitary Gland Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.